QIAGEN (ETR:QIA) Stock Upgrade
In recent note shared with investors on Thursday morning, DZ-Bank AG announced that they have decided to upgrade QIAGEN (ETR:QIA) shares to a “Buy”.
From a total of 6 analysts covering QIAGEN (ETR:QIA) stock, 2 rate it a ”Buy”, 2 a “Sell”, and 2 a ”Hold”. This means that 33% of the ratings are positive. The highest target price is €26 while the lowest target price is €21. The mean of all analyst targets is €23.40 with a -7.14% below today’s (€25.2) stock price. QIAGEN was the topic of 12 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Independent Research downgraded shares on November 6 to “Sell” rating. BNP Paribas downgraded shares to “Underperform” rating and €21 target share price in a report from a July 31. Berenberg upgraded QIA stock in a recent report from October 28 to “Buy” rating. Finally, DZ-Bank AG upgraded the stock to “Buy” rating in a report issued on an August 25.
The stock increased 1.10% or EUR 0.28 on December 2, striking EUR 25.2. Approximately 406,235 shares of stock traded hands or 8.00% up from the average. Qiagen NV (ETR:QIA) has 0.00% since March 4, 2015 and is . It has outperformed by 0.20% the S&P500.
QIAGEN N.V. is a Netherlands holding company. The company has a market cap of 5.85 billion EUR. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. It has 61.12 P/E ratio. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.